Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Actin depolymerization promotes axon regeneration by restoring axonal mitochondrial transport in mouse models of optic neuropathy.
Journal: Science translational medicine
Published: February 25, 2026
NeuProIO: A dual-Action Solid Drug Nanoparticle Topical Formulation for Simultaneous Intraocular Pressure Reduction and Neuroprotection for Glaucoma.
Journal: Chemical engineering journal (Lausanne, Switzerland : 1996)
Published: February 23, 2026
GPX4 Promotes Optic Nerve Regeneration and RGC Neuroprotection.
Journal: bioRxiv : the preprint server for biology
Published: June 12, 2025
GPX4 promotes optic nerve regeneration and retinal ganglion cell neuroprotection.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: June 09, 2025
Optineurin-facilitated axonal mitochondria delivery promotes neuroprotection and axon regeneration.
Journal: bioRxiv : the preprint server for biology
Published: April 15, 2024
Optineurin-facilitated axonal mitochondria delivery promotes neuroprotection and axon regeneration.
Journal: Nature communications
Published: April 10, 2024
Circadian desynchrony in early life leads to enduring autistic-like behavioral changes in adulthood.
Circadian desynchrony in early life leads to enduring autistic-like behavioral changes in adulthood.
Journal: Communications biology
Published: March 01, 2024
Differential effects of SARM1 inhibition in traumatic glaucoma and EAE optic neuropathies.
Journal: Molecular therapy. Nucleic acids
Published: December 12, 2022
Maprotiline restores ER homeostasis and rescues neurodegeneration via Histamine Receptor H1 inhibition in retinal ganglion cells.
Journal: Nature communications
Published: November 23, 2021
Disruption of Circadian Rhythms by Ambient Light during Neurodevelopment Leads to Autistic-like Molecular and Behavioral Alterations in Adult Mice.
Journal: Cells
Published: November 11, 2021
NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: September 10, 2021
Last Updated: 09/26/2026